Company Overview and News

 
Burcon Announces Results of Shareholder Meeting

2018-09-07 globenewswire
VANCOUVER, British Columbia, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX: BU) a leader in functional, renewable plant-based proteins, is pleased to announce the results from its 2018 annual and special meeting of shareholders (the “Meeting”) held on September 6, 2018. All of the seven nominees set out in Burcon’s management proxy circular dated July 19, 2018 proposed by management for election to the board of directors at the Meeting were elected to the board.
BUROF BUR BU

13
Burcon Announces Fiscal 2018 Results and Reviews Operations

2018-06-18 globenewswire
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU), a leader in natural product extraction, purification and isolation technologies, reported results for the year ended March 31, 2018.
BUROF BUR BU

13
Burcon’s Peazazz and Peazac Pea Proteins Receive Self-Affirmed GRAS Status

2018-06-18 globenewswire
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU) (“Burcon” or the “Company”) a leader in natural product extraction, purification and isolation technologies, is pleased to announce the Company’s Peazazz® and Peazac® pea proteins have received self-affirmed Generally Recognized As Safe (GRAS) status, and the Company has officially submitted to the United States Food and Drug Administration (“FDA”) a formal GRAS Notification dossier.
BUROF BUR BU

14
Burcon Announces Delisting From Nasdaq Capital Market

2018-04-25 globenewswire - 1
VANCOUVER, British Columbia, April 25, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BUR) (“Burcon” or the “Company”), a leader in natural product extraction, purification and isolation technologies, announced today that it received a letter, dated April 25, 2018, from the Nasdaq Hearings Panel (the “Panel”) of The NASDAQ Stock Market LLC (“Nasdaq”) informing the Company that the Panel has determined to delist the Company’s common shares from the Nasdaq Capital Market and will suspend trading in the shares effective at the open of business on April 27, 2018.
BUR OTCM BU

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:BU / Burcon Nutrascience Corp on message board site Silicon Investor.

Buy and Sell Signals, and Other Market Perspectives Buy and Sell Signals, and Other Market Perspectives Buy and Sell Signals, and Other Market Perspectives TNRG Tianrong Building Materials TNRG Tianrong Building Materials TNRG Tianrong Building Materials
Sudbury Saturday Night -- Nickel Mining u0026 Nickel Prices Sudbury Saturday Night -- Nickel Mining u0026 Nickel Prices Sudbury Saturday Night -- Nickel Mining u0026 Nickel Prices The New QUALCOMM - Coming Into Buy Range The New QUALCOMM - Coming Into Buy Range The New QUALCOMM - Coming Into Buy Range
BuSab BuSab BuSab Bodybuilding Bodybuilding Bodybuilding
Computer Building Computer Building Computer Building A.I.M Users Group Bulletin Board A.I.M Users Group Bulletin Board A.I.M Users Group Bulletin Board
Booms, Busts, and Recoveries Booms, Busts, and Recoveries Booms, Busts, and Recoveries Silver Bull Resources, Inc. Silver Bull Resources, Inc. Silver Bull Resources, Inc.